Goldstein EJC - Search Results

1

Effects of control interventions on Clostridium difficile infection in England: an observational study.

Dingle KE, Didelot X, Quan TP, Eyre DW, Stoesser N, Golubchik T, Harding RM, Wilson DJ, Griffiths D, Vaughan A, Finney JM, Wyllie DH, Oakley SJ, Fawley WN, Freeman J, Morris K, Martin J, Howard P, Gorbach S, Goldstein EJC, Citron DM, Hopkins S, Hope R, Johnson AP, Wilcox MH, Peto TEA, Walker AS, Crook DW; Modernising Medical Microbiology Informatics Group. Dingle KE, et al. Among authors: goldstein ejc. Lancet Infect Dis. 2017 Apr;17(4):411-421. doi: 10.1016/S1473-3099(16)30514-X. Epub 2017 Jan 25. Lancet Infect Dis. 2017. PMID: 28130063 Free PMC article.

2

Reproducibility of broth microdilution and comparison to agar dilution for testing CB-183,315 against clinical isolates of Clostridium difficile.

Citron DM, Goldstein EJ. Citron DM, et al. Diagn Microbiol Infect Dis. 2011 Aug;70(4):554-6. doi: 10.1016/j.diagmicrobio.2011.04.012. Diagn Microbiol Infect Dis. 2011. PMID: 21767714

3

Ridinilazole: a novel therapy for Clostridium difficile infection.

Vickers RJ, Tillotson G, Goldstein EJ, Citron DM, Garey KW, Wilcox MH. Vickers RJ, et al. Int J Antimicrob Agents. 2016 Aug;48(2):137-43. doi: 10.1016/j.ijantimicag.2016.04.026. Epub 2016 May 30. Int J Antimicrob Agents. 2016. PMID: 27283730 Free article. Review.

4

Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II.

Goldstein EJC, Citron DM, Gerding DN, Wilcox MH, Gabryelski L, Pedley A, Zeng Z, Dorr MB. Goldstein EJC, et al. Clin Infect Dis. 2020 Aug 14;71(4):1102-1105. doi: 10.1093/cid/ciz1151. Clin Infect Dis. 2020. PMID: 31883370 Free article. Clinical Trial.

5

In vitro activity of DS-2969b and comparator antimicrobial agents against Clostridioides (Clostridium) difficile, methicillin-resistant Staphylococcus aureus, and other anaerobic bacteria.

Tyrrell KL, Citron DM, Merriam CV, Leoncio E, Goldstein EJC. Tyrrell KL, et al. Among authors: goldstein ejc. Anaerobe. 2018 Dec;54:39-41. doi: 10.1016/j.anaerobe.2018.04.010. Epub 2018 Apr 13. Anaerobe. 2018. PMID: 30096588

6

Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria.

Citron DM, Warren YA, Tyrrell KL, Merriam V, Goldstein EJ. Citron DM, et al. J Antimicrob Chemother. 2009 May;63(5):972-6. doi: 10.1093/jac/dkp037. Epub 2009 Feb 24. J Antimicrob Chemother. 2009. PMID: 19240076

7

Activity of a novel carbapenem, doripenem, against anaerobic pathogens.

Goldstein EJ, Citron DM. Goldstein EJ, et al. Diagn Microbiol Infect Dis. 2009 Apr;63(4):447-54. doi: 10.1016/j.diagmicrobio.2009.01.022. Epub 2009 Feb 26. Diagn Microbiol Infect Dis. 2009. PMID: 19249176 Review.

8

C. difficile infection (CDI) in a long-term acute care facility (LTAC).

Goldstein EJ, Polonsky J, Touzani M, Citron DM. Goldstein EJ, et al. Anaerobe. 2009 Dec;15(6):241-3. doi: 10.1016/j.anaerobe.2009.06.009. Epub 2009 Aug 13. Anaerobe. 2009. PMID: 19683064

9

Bactericidal activity of telavancin, vancomycin and metronidazole against Clostridium difficile.

Goldstein EJ, Citron DM, Tyrrell KL, Warren YA. Goldstein EJ, et al. Anaerobe. 2010 Jun;16(3):220-2. doi: 10.1016/j.anaerobe.2009.12.002. Epub 2010 Jan 4. Anaerobe. 2010. PMID: 20044011

10

Activity of garenoxacin against 536 unusual anaerobes including 128 recovered from acute pelvic infections.

Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV. Goldstein EJ, et al. Diagn Microbiol Infect Dis. 2011 May;70(1):131-6. doi: 10.1016/j.diagmicrobio.2010.12.006. Epub 2011 Mar 12. Diagn Microbiol Infect Dis. 2011. PMID: 21398076

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

455 results

Search Page